Role of metabolic syndrome components in HIV-associated sensory neuropathy

Objectives:Sensory neuropathy is a common peripheral nerve complication of HIV infection and highly active antiretroviral therapy. Metabolic syndrome (MetS), a cluster of risk factors for atherosclerosis and microvascular disease, is associated with sensory neuropathy in HIV-uninfected (HIV-negative) persons. We examined whether MetS or its components predispose individuals to HIV-associated sensory neuropathy (HIV-SN). Design:From a prospective multicenter cohort of 1556 HIV-positive patients, a subgroup (n = 130) with fasting laboratory tests and sensory neuropathy assessment was selected. Methods:Sensory neuropathy was defined by symmetrically decreased reflexes or sensation loss in the legs. MetS was defined by presence of at least three risk factors: mean arterial pressure of at least 100 mmHg; triglycerides (TRGs) of at least 150 mg/dl and high-density lipoprotein cholesterol of less than 40 mg/dl for male patients, less than 50 mg/dl for female patients; body mass index of more than 25 kg/m2; plasma glucose (GLU) of at least 100 mg/dl and self-reported diabetes mellitus type 2. Multivariate logistic regression examined the association between HIV-SN and MetS. Results:After controlling for HIV-SN risk factors such as age, CD4 current, length of HIV infection, use of dideoxynucleoside reverse transcriptase inhibitors and protease inhibitors, MetS was not associated with HIV-SN (P = 0.72). However, when each MetS component was assessed, elevated TRG was a significant risk factor for HIV-SN. From the larger cohort, both diabetes mellitus type 2 (odds ratio = 1.4, P < 0.01) and elevated TRG (odds ratio = 1.4, P = 0.01) were risk factors for HIV-SN. Conclusion:The risk of HIV-SN was increased for diabetes mellitus type 2 and elevated TRG but not for other MetS components. Both increase the risk of sensory neuropathy in HIV-populations, but the mechanism(s) remains unclear.

[1]  I. Grant,et al.  Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy , 2008, Annals of neurology.

[2]  D. Simpson,et al.  Diagnosis and management of HIV-associated neuropathy. , 2008, Neurologic clinics.

[3]  F. Rodríguez‐Artalejo,et al.  Effectiveness of Blood Pressure Control Outside the Medical Setting , 2007, Hypertension.

[4]  D. Clifford,et al.  HIV neuropathy natural history cohort study , 2006, Neurology.

[5]  X. Pi-Sunyer,et al.  The metabolic syndrome: how to approach differing definitions. , 2007, The Medical clinics of North America.

[6]  S. Azar,et al.  Hypertriglyceridemia and peripheral neuropathy in neurologically asymptomatic patients. , 2005, Neuro endocrinology letters.

[7]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[8]  H. Sone,et al.  Vascular risk factors and diabetic neuropathy. , 2005, The New England journal of medicine.

[9]  Daniel W. Jones,et al.  Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. , 2005, Hypertension.

[10]  D. Simpson,et al.  HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. , 2004, Archives of neurology.

[11]  J. Gross,et al.  Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in Type 2 diabetes , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[12]  K. Marder,et al.  Incidence of and risk factors for HIV-associated distal sensory polyneuropathy , 2002, Neurology.

[13]  C. Autore,et al.  Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents. , 2002, Italian heart journal : official journal of the Italian Federation of Cardiology.

[14]  L. Groop,et al.  The metabolic syndrome influences the risk of chronic complications in patients with Type II diabetes , 2001, Diabetologia.

[15]  D. Cooper,et al.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.

[16]  B. Swanson,et al.  HIV-associated distal symmetrical polyneuropathy: clinical features and nursing management. , 1998, The Journal of the Association of Nurses in AIDS Care : JANAC.

[17]  J. Becker,et al.  Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. , 1994, Neurology.

[18]  M. Górgolas Hernández-Mora,et al.  [Clinical and subclinical neuropathy in patients with human immunodeficiency virus receiving antiretroviral therapy]. , 2006, Revista de neurologia.

[19]  S. Dorsey,et al.  HIV peripheral neuropathy: pathophysiology and clinical implications. , 2006, AACN clinical issues.

[20]  K. Lichtenstein,et al.  Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  J. McArthur,et al.  Recent developments in the HIV neuropathies. , 2003, Current opinion in neurology.

[22]  M. Tagliati,et al.  Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings. , 1999, Archives of neurology.